Cellusion Inc.
Production of replacement cells for the corneal endothelium from iPS cells, bringing light to patients waiting for a transplant
Cellusion aims to realize a new treatment method that manufactures corneal endothelium replacement cells from iPS cells using a unique method and transplants them into the eye. The surgery involves simply injecting cells with a syringe, and the cells settle into the cornea three hours after surgery. The graft survival of transplanted cells has already been confirmed in experiments on monkeys and other animals and we are currently making preparations for clinical research. By realizing this treatment, we aim to provide a solution for 13 million patients waiting for transplants worldwide.
- Establishment Date
- January 2015
- Business
- Regenerative medicine using iPS-derived corneal endothelial cells
- CEO
- Shin Hatou, CEO
KII’s Perspective
It may be possible to provide groundbreaking medical treatment that solves the problem of a lack of donors for corneal transplants. Since this is a simple procedure, it can be expected that Cellusion’s products will be provided not only in developed countries but also in emerging countries.
KII growth support
Financing assistance, Business alliance support, Recruitment support, Public relations support, Appointment of directors
